Sustained low‐dose interleukin‐2 therapy alleviates pathogenic humoral immunity via elevating the Tfr/Tfh ratio in lupus

Sustained low‐dose interleukin‐2 therapy alleviates pathogenic humoral immunity via elevating the Tfr/Tfh ratio in lupus

Abstract Objectives Low‐dose interleukin‐2 (IL‐2) has shown promising clinical benefits in the treatment of systemic lupus erythematosus (SLE), but how this therapy alleviates pathogenic humoral immunity remains not well understood. The dilemma is that IL‐2 can suppress both follicular helper and re...

Full description

Bibliographic Details
Main Authors: Kaili Liang, Jing He, Yunbo Wei, Qunxiong Zeng, Dongcheng Gong, Jiahuan Qin, Huihua Ding, Zhian Chen, Ping Zhou, Peng Niu, Qian Chen, Chenguang Ding, Liangjing Lu, Xiao‐Xiang Chen, Zhanguo Li, Nan Shen, Di Yu, Jun Deng
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Clinical & Translational Immunology
Subjects:
B cell
humoral immunity
interleukin‐2
systemic lupus erythematosus
Tfr/Tfh ratio
Online Access:https://doi.org/10.1002/cti2.1293

Internet

https://doi.org/10.1002/cti2.1293

Similar Items